Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteraemia
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
Phase IV, open-labeled, randomized and multicenter clinical trial to demonstrate the
superiority of antibiotics with authorized indication for 7 days versus 14 days in the
treatment of bloodstream infections produced by P. aeruginosa (BSI-PA).
Phase:
Phase 4
Details
Lead Sponsor:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Collaborators:
CIBER (Infectious diseases) Spanish Clinical Research Network - SCReN